Two short-acting benzodiazepines, midazolam 15 mg and triazolam 0.25 mg, were compared with diazepam 10 mg and placebo as oral premedicants in 120 patients presenting for minor urological surgery. Midazolam was found to produce the greatest degree of amnesia and sedation at the time of anaesthetic induction and triazolam was found to have the greatest degree of residual sedation at the time of discharge, four hours postoperatively. These effects are consistent with the greater potency and more rapid onset of action of midazolam at this dose compared with triazolam. The relative merits of the compounds as anxiolytics varied depending upon the observer, time and method of assessment. It was considered that the doses of midazolam and triazolam used were excessive for routine day case anaesthesia.
result in a small but prolonged impairment of psychomotor performance.
Of the clinically available benzodiazepines, midazolam and triazolam possess the shortest elimination half-lives (approximately 2.5 hours), a feature which makes them potentially useful short-acting day-case anxiolytics.
Oral triazolam has been used' for outpatient anaesthesia 4 and midazolam has been shown to be a promising premedicant by the intramuscular route. 5 The purpose of this study was to compare oral preparations of these short-acting benzodiazepines with each other and with diazepam and placebo for daystay anaesthesia. METHODS One hundred and twenty patients presenting for minor, day-stay, urological surgery were admitted to the study. All patients gave informed consent, were ASA 1-2 and between the ages of 20-60 years.
Approximately 90 minutes prior to surgery, patients were randomly allocated to receive, in a double-blind manner, one of four oral premedicants from coded envelopes, placebo, triazolam 0.25 mg, midazolam 15 mg or diazepam 10 mg. The triazolam and midazolam doses were chosen to give a comparable duration of action of approximately six hours. 6 Anaesthesia for each group comprised induction with methohexitone (increments as required to produce loss of lash reflex) and fentanyl, 1 Ilglkg, intravenously. Maintenance of anaesthesia was provided with N20 70% via a circle absorption system and halothane 0.5% increments as required.
At the time of premedication and again immediately prior to induction of anaesthesia, anxiety and sedation were assessed by giving patients standard visual analogue scales of anxiety and sedation.
Psychomotor performance was assessed using a letter deletion test. This was administered before premedication, at immediately before induction, and at times 30 minutes, two hours and four hours postoperatively. The letter deletion test comprised 30 lines of 25 randomly typed upper and lower-case letters, the subjects were asked to delete as many letters g or G in a twominute time interval as possible. The test score was taken as the number of lines completed minus half the number of errors (there were approximately two g or Gs per line).
Amnesia was assessed by showing patients simple line diagrams before premedication, before induction and at 30 minutes, two hours and four hours postoperatively. Patients were asked to recall these 24 hours following surgery.
At the time of induction the anaesthetist recorded on visual analogue scales his perception of the patient's degree of anxiety, overall assessment of the premedication, quantity of oral secretions when a Guedel airway was inserted following induction, severity of pain on injection ofmethohexitone and severity of involuntary muscle movements.
At the time of discharge, four hours postoperatively, patients were seen by another anaesthetist who assessed their degree of sedation on a visual analogue scale and clinically examined the degree of sway using Romberg's test. The recovery room nursing staff assessed the quality of recovery at this time, also using a visual analogue scale.
Prior to discharge and on the day following surgery a questionnaire was completed by patients, attempting to assess their recovery, attitudes towards the premedication and possible side-effects resulting from it.
Statistical analysis
Non-parametric comparison of categorical data was made using a chi squared test and non-parametric ordinal data (as in the four hour and 24 hour questionnaires) was analysed by the Kruskal-Wallis test (an analysis of variance of ranks).
Visual analogue scale assessments by anaesthetist and nursing staff were analysed by an analysis of variance (ANOV A). Subjective visual analogue scale sedation and anxiety data, letter deletion test and physiological variables were examined by an analysis of covariance (ANCQY A) with the covariate taken as the unpremedicated value. Specific drugs were only compared with each other when analysis for differences within the group as a whole achieved a level of significance of less than or equal to 0.05. Table 1 shows demographic and anaesthetic data for the four groups. No significant age or sex differences were present. However, the midazolam group was found to be heavier than the placebo.
RESULTS
The mean change in sedation and anxiety 100 Time (mins) In Tables 2,3 and 4 the Pvalues found when comparing each drug with placebo at each time interval for the sedation scores, letter deletion tests, and line diagram recall are shown.
In Tables 5 and 6 the responses to the fourhour and 24-hour questionnaire are given and in Table 7 the assessments made by the anaesthetist and nursing staff.
Two patients in the midazolam group were too sedated (one unrousable) to complete the preinduction assessments.
Anxiety
The lowest subjective anxiety scores were recorded for the midazolam and triazolam groups, although no significant overall between-groups difference was found (P = 0.7). However, assessment of anxiety by the anaesthetist at the time of induction showed significantly greatest anxiolysis with midazolam.
In contrast, when patients were questioned at 24 hours regarding the effect of the tablet on preoperative anxiety a significant variation was found, with triazolam being perceived as more anxiolytic than either placebo, midazolam or diazepam. Patients recalled they felt 'better' after the triazolam than diazepam, placebo or midazolam. Two patients claimed to feel worse after the midazolam than before premedication.
Heart rate and blood pressure changes did not differ significantly between groups. 
Sedation
At the time of induction the visual analogue scale sedation score significantly differed for the four groups. A comparison of individual drug effects showed that both midazolam and triazolam produced significantly greater subjective sedation than diazepam, which in turn was significantly greater than placebo.
On recovery from anaesthesia there was a significant variation in the time to open eyes on command with the slowest recovery in the triazolam and midazolam groups.
No significant between-groups difference was found in the sedation score at 30 minutes postoperatively. However, by two hours there was a large significant variation with the triazolam group subjectively more sedated than the midazolam group, which was more sedated than either the diazepam or placebo groups. On discharge at four hours a significant between-groups variation persisted with the triazolam group subjectively more sedated than placebo. This was not so, however, for the diazepam or midazolam groups.
At four hours a significant difference was found between groups on questioning as to whether they felt fully awake and back to their normal selves, the slowest recovery being noted for triazolam. However, no difference was found in patients feeling ready to leave for home and when questioned the following day no difference was noted with difficulties m getting home.
On arrival home almost one-third of patients in each group slept for a period.
After 24 hours the least number of patients feeling fully back to normal was in the placebo group.
Amnesia
Recall of simple line diagrams at 24 hours revealed no significant differences in the amnesic effects of the benzodiazepine premedicants prior to induction and at 30 minutes and two hours postoperatively. Prior to induction, compared with placebo, significant amnesia was found only for midazolam. By 30 minutes postoperatively, both triazolam and midazolam produced significantly greater amnesia than placebo. However, by two hours midazolam was the only premedicant with significantly greater amnesia. By four hours there were no between-groups differences.
Although not significant, the lowest recall of Performance At all times up to four hours there was a highly significant between-groups difference in objective performance assessed by the letter deletion test. Initial performance at the time of induction was impaired by all of the premedicants, and to the greatest extent by midazolam. Both triazolam and midazolam were associated with reduced scores up to and including four hours, at which time they showed significantly greater impairment than diazepam which did not differ significantly from placebo.
On questioning at four hours, patients did not differ in their own assessment of whether or not they felt they could perform their normal day-to-day activities or safely drive a motor vehicle.
Anaesthetic effects
No significant differences were found between the groups with regard to the required dose of methohexitone (P = 0.65), halothane requirements (P = 0.63), severity of involuntary muscle movements (P = 0.96), Comparison with placebo; *P < 0.01. tP < 0.001 injection pain (P = 0.7) or oral secretions (P= 0.17).
Overall assessment of premedicants When anaesthetists were asked to assess the overall appropriateness of the effect of premedication no significant difference was found between groups. However, the relative, decreasing order of appropriateness was triazolam, diazepam, midazolam and then placebo. Asked if they were willing to use the same premedicant again, the decreasing frequency of preference was midazolam equal to diazepam, then triazolam and finally placebo.
When patients were asked if they were happy to receive the same premedicant again, midazolam and triazolam were the most popular, then diazepam and placebo. However, these differences were not significant.
DISCUSSION
Midazolam and triazolam are benzodiazepines with short elimination halflives. After oral ingestion both compounds are rapidly cleared and plasma levels fall, by six hours, to 12% and 34% of the peak plasma level for midazolam and triazolam respectively. Both are broken down to active metabolites. However, the elimination halflives of these are short and although potentiating the parent drug, do not result in any prolongation of its action. 6, 7 Because of their favourable kinetic profiles triazolam and midazolam are likely to have a place as preoperative day-case anxiolytics.
In this study we found that each of the medications including placebo was acceptable to patients and anaesthetist. Midazolam 15 mg produced the greatest degree of amnesia, sedation and impairment of performance one and a half hours following ingestion. At the time of discharge triazolam 0.25 mg was associated with the greatest degree of residual sedation. These observations are consistent with a greater potency and more rapid offset of effect of midazolam 15 mg compared with triazolam 0.25 mg. Extrapolated for equal degrees of sedation, therefore, midazolam has a more rapid clinical recovery. The considerably less potent dose of diazepam (10 mg) differed little from placebo and did not significantly result in residual effects.
The relative anxiolytic effects varied depending on the assessor, time, and method of assessment. Midazolam was observed by anaesthetists to produce the greatest anxiolysis at the time of induction. However, the patient's own assessment (visual analogue scale) showed no differences between the medications and placebo. In contrast, patients when asked at 24 hours remembered triazolam as giving the greatest anxiolysis and making them feel 'better'.
The lack of demonstrated anxiolytic effects over that of placebo on the visual analogue scale was unexpected, but the difficulties with this method of assessment have been commented upon previously.9 Possible reasons for this finding may include the use of small patient numbers, the use of patients with low baseline levels of anxiety, a ceiling effect to benzodiazepine anxiolysis, a fundamental difference between the state of 'anxiety' perceived by the patients and that which we assume is recorded on the visual analogue scale, and with increasing benzodiazepine sedation, the patient's perception of anxiety may be distorted, as may his ability to make an assessment on the scale.
The anaesthetist's assessment showed midazolam to be the most anxiolytic while the patient's recall of anxiolysis favoured triazolam. These observations may be related either to amnesia (as a high percentage of patients in the midazolam group had little recall for the preinduction period) or a confusion between sedation and anxiety on the part of the anaesthetist. Whatever the reasons for the variation in the apparent anxiolytic effects of the medications it seems necessary that at least three aspects of the anxiolytic effect of a medication be examined; the patient's own perceived anxiety, an observer's perception of anxiety (which incorporates physiological, e.g. hormonal, responses) and the patient's memory of the anxiety.
Amnesia may be a desirable property of anxiolytic medications. However, in day-case surgery where patients frequently return for repeat procedures (e.g. endoscopy), amnesic premedication may prevent the patient becoming accustomed to, and therefore less anxious with, each subsequent visit. The use of amnesic doses of benzodiazepines is probably of greatest value for more stressful procedures, and for routine anaesthesia many patients prefer to have full recall. 9 All benzodiazepines act at specific receptor sites within the brain and spinal cord. These central receptors have been classified into receptor subtypes on the basis of varying affinity for different benzodiazepines. lo Two subtypes are claimed to mediate selectively the effects of sedation and anxiety. It is possible therefore that receptor heterogeneity may explain the apparent differences between the anxiolytic and sedative effects of the medications examined in this study. However, we believe our findings do not necessarily reflect intrinsic differences in the amnesic, anxiolytic and sedative properties of the drugs tested but rather can be explained simply on the basis of differing potency and pharmacokinetic profiles. With the exception of the patient's visual analogue scale anxiety ratings, the differential effects of the three benzodiazepines were in proportion to their relative potencies (midazolam 15 mg > triazolam 0.25 mg > diazepam 10 mg > placebo).
In summary, we found the new short-acting benzodiazepines to be promising day-case premedicants. However, the doses of triazolam and midazolam were too high for routine use. The duration of action of 0.25 mg triazolam was excessive and a dose of 15 mg of midazolam was too sedative at the time of induction. With appropriate adjustment in dose both premedicants would be of value for outpatient surgery, although midazolam appears to have the greatest flexibility with regard to potency and short duration of action.
